NASDAQ:OPRX
OptimizeRx Corp
OptimizeRx Corp's revenue grew 18.8% in fiscal 2025 to $109.4M while operating margin rose to 10.7%, its highest in 10 years. Free cash flow was $18.7M, 17.0% of revenue, and the diluted share count rose 3.9%.Summary generated from OptimizeRx Corp's SEC filings. Latest annual report filed Mar 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$109.4M
Revenue growth+18.8%
Revenue, 5-yr CAGR+20.4%
Gross margin67.3%
Operating margin10.7%
Net margin4.7%
ROIC6.4%
Return on equity4.2%
Debt / equity0.20
Free cash flow$18.7M
FCF margin17.0%
Share count change+3.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 61 | 62 | 72 | 92 | 109 |
| Operating income | 0 | −12 | −26 | −14 | 12 |
| Net income | 0 | −11 | −18 | −20 | 5 |
| Free cash flow | 1 | 11 | −7 | 5 | 19 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Sep 2, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 8-KDirector or officer change
Jun 12, 2026 - 8-KDirector or officer change
Jun 5, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KEntry into a material agreement
May 12, 2026